Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) Comparison with companies in other sectors?

Fujian Haixi Pharmaceuticals Co., Ltd. has a share price of 78.71M. You can analyze Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) competitors across different market sectors through stock heatmaps.

What are 2637.HK's NET and operating margins?

Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) operating margin is around N/A, and net profit margin is approximately N/A as of the latest reports.

In what way does 2637.HK's earnings per share (EPS) trend reflect its financial momentum?

Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) EPS is 2.95 (If EPS value is positive, then "signals consistent profit growth" if Negative then "signals consistent loss"). This metric is also critical in assessing valuation metrics like the P/E ratio for Fujian Haixi Pharmaceuticals Co., Ltd. is 63.39, and the company's ability to reinvest or distribute profits.

What does a high ROE mean for Fujian Haixi Pharmaceuticals Co., Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Fujian Haixi Pharmaceuticals Co., Ltd. like P/E which is N/A, P/B which is N/A, and PEG which is N/A. Compare them with sector averages to evaluate if the stock is priced fairly.

Fujian Haixi Pharmaceuticals Co., Ltd. Fundamental Analysis

2637.HK●HKSE

HealthcareDrug Manufacturers - Specialty & Generic

HK$187.00

HK$5.80(3.008%)

Hong Kong Market opens in 43h 50m

Fujian Haixi Pharmaceuticals Co., Ltd. Fundamental Analysis

Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) shows weak financial fundamentals with a PE ratio of 63.39, profit margin of N/A, and ROE of N/A. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

No significant strengths identified.

Areas of Concern

No major concerns flagged.

We analyze 2637.HK's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 0.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

0.0/100

We analyze 2637.HK's fundamental strength across five key dimensions:

Efficiency Score

Weak

2637.HK struggles to generate sufficient returns from assets.

ROA > 10%

N/A

Valuation Score

Weak

2637.HK trades at a premium to fair value.

PE < 25

63.39

PEG Ratio < 2

N/A

Growth Score

Moderate

2637.HK shows steady but slowing expansion.

Revenue Growth > 5%

N/A

EPS Growth > 10%

N/A

Financial Health Score

Weak

2637.HK carries high financial risk with limited liquidity.

Debt/Equity < 1

N/A

Current Ratio > 1

N/A

Profitability Score

Weak

2637.HK struggles to sustain strong margins.

ROE > 15%

N/A

Net Margin ≥ 15%

N/A

Positive Free Cash Flow

N/A

Key Financial Metrics

Is 2637.HK Expensive or Cheap?

P/E Ratio

2637.HK trades at 63.39 times earnings. This suggests a premium valuation.

63.39

How Well Does 2637.HK Make Money?

No data available.

Following the Money - Real Cash Generation

No data available.

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

N/A

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

N/A

vs 25 benchmark

P/B Ratio

Price to book value ratio

N/A

vs 25 benchmark

P/S Ratio

Price to sales ratio

N/A

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

N/A

vs 25 benchmark

Current Ratio

Current assets to current liabilities

N/A

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

N/A

vs 25 benchmark

ROA

Return on assets percentage

N/A

vs 25 benchmark

ROCE

Return on capital employed

N/A

vs 25 benchmark

How 2637.HK Stacks Against Its Sector Peers

Metric	2637.HK Value	Sector Average	Performance
P/E Ratio	N/A	29.60	N/A
ROE	N/A	418.00%	N/A
Net Margin	N/A	-11442.00% (disorted)	N/A
Debt/Equity	N/A	0.78	N/A
Current Ratio	N/A	5.13	N/A
ROA	N/A	-74.00% (disorted)	N/A

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Fujian Haixi Pharmaceuticals Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fujian Haixi Pharmaceuticals Co., Ltd. Fundamental Analysis

Key Strengths

Areas of Concern

Fundamental Health Score

Efficiency Score

Valuation Score

Growth Score

Financial Health Score

Profitability Score

Key Financial Metrics

Is 2637.HK Expensive or Cheap?

How Well Does 2637.HK Make Money?

Following the Money - Real Cash Generation

Financial Ratios Analysis

Valuation Ratios

Financial Health

Efficiency Ratios

How 2637.HK Stacks Against Its Sector Peers

Historical Growth Performance

5-Year Growth Trajectory

Fundamental Analysis FAQ

Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) Comparison with companies in other sectors?

What are 2637.HK's NET and operating margins?

In what way does 2637.HK's earnings per share (EPS) trend reflect its financial momentum?

What does a high ROE mean for Fujian Haixi Pharmaceuticals Co., Ltd.?

How do I know if AAPL is overvalued or undervalued?